Related Experiment Video
Updated: Jan 10, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Reproductive Considerations of Gene Therapies for Sickle Cell Disease and Beta-Thalassemia
Kimia Sorouri1, Edward R Scheffer Cliff2, Karen B Glass3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Obstetrics and Gynaecology, University of Alberta, Edmonton, AB.
Abstract:
Gene therapies for sickle cell disease and beta-thalassemia offer potentially curative treatment for patients aged ≥12 years but require gonadotoxic myeloablative conditioning. Fertility preservation and hormone replacement are essential components of standard care for ex vivo gene therapies.
More Related Videos
Related Concept Videos
Gene Therapy
Multiple Allele Traits
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
What is Genetic Engineering?
iPS Cell Differentiation
Microorganisms in Medicine and Therapeutics

